News

For the first quarter of 2011, the company’s net income was EUR1.29bn, compared to EUR1.79bn in the prior year period. The company has generated gross profit of EUR5.83bn,

INNO-206 is intended to control the release of chemotherapeutic doxorubicin and to preferentially target tumors, which the company believes may make it more effective and less toxic in

The company posted a gross profit of $337.91m for the first quarter of 2011, compared to $343.46m for the same period in 2010. For the first quarter of

For the third quarter ended 31 March 2011, the company’s loss from operations was $15.1m, as compared to $12.22m for the same period last year. ImmunoGen has posted

The trial aims to characterize the safety profile of NTx-428 when administered to patients who have sustained a TBI. The company expects to complete the recruitment of 10

Research and development expenses were $3.3m, compared to $1.1m for the same period in 2010, primarily related to the advancement of the Phase III clinical development program for

Patients eligible for this comparative study are previously treated with an anthracycline and a taxane during first-line therapy for metastatic disease. Phase 2 trial underlines Phase 1 eniluracil/5-FU/leucovorin

Vyvanse, a prescription medicine used for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD), is administered orally as adjunctive therapy. Vyvanse was administered to 92 clinically stable patients with predominant

VEGF Trap-Eye, a human fusion protein and a highly potent blocker of the growth factors, is believed to decrease vascular permeability and edema and prevent the inappropriate growth